I have held leadership positions in cancer centers at University of California San Diego (founding director), Memorial Sloan Kettering Cancer Center (Chairman of Medicine), and MD Anderson (President). My colleagues and I produced a novel monoclonal antibody against the EGF receptor, cetuximab, which was the first reported agent that prevented activation of a receptor tyrosine kinase and inhibited cell proliferation, and we performed the first clinical trial with a tyrosine kinase inhibitor. I served as founding editor-in-chief of Clinical Cancer Research and lead editor of the Molecular Basis of Cancer for four editions.
I am honoured to have been elected the founding chairman of the WIN consortium. I have been elected to the Institute of Medicine and the American Academy of Arts and Sciences.
Dr. John Mendelsohn was named Chairman Emeritus on June 24th, 2018.
“I have been striving to bring targeted cancer into the clinic for more than three decades. WIN is carrying this goal forward, globally.”